Diphenhydramine and phenylephrine and Fedratinib Hydrochloride
Determining the interaction of Diphenhydramine and phenylephrine and Fedratinib Hydrochloride and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration of fedratinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C19, or 2D6 isoenzymes. Coadministration of fedratinib with a single dose each of the CYP450 3A4 substrate midazolam (2 mg), CYP450 2C19 substrate omeprazole (20 mg), and CYP450 2D6 substrate metoprolol (100 mg) increased the systemic exposure (AUC) of the substrates by 4-, 3-, and 2-fold, respectively. MANAGEMENT: Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index. References "Product Information. Inrebic (fedratinib)." Celgene Corporation, Summit, NJ.
Professional:MONITOR: Coadministration of fedratinib may increase the plasma concentrations of drugs that are substrates of CYP450 3A4, 2C19, or 2D6 isoenzymes. Coadministration of fedratinib with a single dose each of the CYP450 3A4 substrate midazolam (2 mg), CYP450 2C19 substrate omeprazole (20 mg), and CYP450 2D6 substrate metoprolol (100 mg) increased the systemic exposure (AUC) of the substrates by 4-, 3-, and 2-fold, respectively.
MANAGEMENT: Caution is recommended when fedratinib is used concomitantly with substrates of CYP450 3A4, 2C19, or 2D6. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever fedratinib is added to or withdrawn from therapy, particularly those with a narrow therapeutic index.
- "Product Information. Inrebic (fedratinib)." Celgene Corporation, Summit, NJ.
Generic Name: diphenhydramine / phenylephrine
Brand name: Children's Triacting Night Time, Delsym Children's Night Time Cough & Cold, Dimetapp Nighttime Cold & Congestion, Dytan-D, PediaCare Children's Allergy & Cold, Robitussin Night Time Cough & Cold, Triaminic Night Time Cold & Cough, Diphentann-D, D-Tann, Uni-Tann D, Aldex-CT, Diphenmax D, Alahist LQ, Robitussin Night Time Cough & Cold Pediatric, Robitussin Night Time Cough & Cold Children's, Delsym Children's Nighttime Cough and Cold, Zoden PD, Benadryl-D Children's Allergy & Sinus, Children's Allergy Plus Congestion, PediaCare Children's NightRest, Children's Triaminic Cough/Cold Nighttime, Theraflu Cold/Cough Nighttime
Synonyms: n.a.
Generic Name: fedratinib
Brand name: Inrebic
Synonyms: Fedratinib
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Diphenhydramine and phenylephrine-Feiba
- Diphenhydramine and phenylephrine-Feiba NF
- Diphenhydramine and phenylephrine-Feiba VH Immuno
- Diphenhydramine and phenylephrine-Feiba-VH
- Diphenhydramine and phenylephrine-Felbamate
- Diphenhydramine and phenylephrine-Felbamate Oral Suspension
- Fedratinib Hydrochloride-Diphenhydramine and Phenylephrine Liquid, Solution, and Syrup
- Fedratinib Hydrochloride-Diphenhydramine and Phenylephrine Oral Strips
- Fedratinib Hydrochloride-Diphenhydramine Capsules
- Fedratinib Hydrochloride-Diphenhydramine Capsules and Tablets
- Fedratinib Hydrochloride-Diphenhydramine Chewable Tablets and Orally-Disintegrating Tablets
- Fedratinib Hydrochloride-Diphenhydramine Elixir, Liquid, and Syrup